How Risky Is Moderna Stock Right Now?
A vaccine capable of safely protecting everyone from the novel coronavirus would be a priceless treasure. This simple connection has been picked up on by hordes of investors who keep throwing money at companies with SARS-CoV-2 vaccine candidates in their pipelines.
Quickly moving a new vaccine candidate into a mid-stage clinical trial drove Moderna's (NASDAQ: MRNA) stock price 230% higher this year. Unfortunately, this means the stock has a long way to fall if the company's SARS-CoV-2 vaccine candidate, mRNA-1273, doesn't swiftly become a huge success.
Image source: Getty Images.
Source Fool.com
